title: In vivo cryochemotherapy of a human lung cancer model.
abstract: Cryotherapy, an efficient technique to destroy tumour cells, is sometimes applied locally as a palliative treatment in lung cancers. It can be performed in combination with chemotherapy. Our aims were to determine in vivo: (1) the effects of cryochemotherapy in a human lung adenocarcinoma, (2) if it presents a benefit compared to the separate treatments and (3) if cryotherapy allows a tumour retention of the drug. Cells from the A549 cell line were xenografted into SCID mice. Tumours were treated by cryotherapy, chemotherapy (injection of Vinorelbine: Navelbine) or both and were studied morphologically at variable time points. Apoptosis was analysed by immunohistochemical staining of cleaved caspase-3 and by TUNEL. Intratumour Navelbine concentration was assessed by high performance liquid chromatography. Necrosis was important 2 h after cryochemotherapy (45% of the tumour surface) and at the later time points. Expression of cleaved caspase-3 was not significantly different from that of untreated tumours, except at the time point of 2 h where it was maximal (58%). Navelbine concentration was more important in tumours treated by chemotherapy than in tumours treated by cryochemotherapy, demonstrating that in our model, the benefit of the association observed 2h after treatment was not due to a concentration-dependent effect.
authors.affiliation: Upres-EA3063, Faculté de Médecine Jacques Lisfranc, 15 rue Ambroise Paré, 42023 Saint-Etienne cedex 02, France. Valerie.Forest@univ-st-etienne.fr
authors.forename: Valérie
authors.initials: V
authors.lastname: Forest
authors.forename: Michel
authors.initials: M
authors.lastname: Peoc'h
authors.forename: Claude
authors.initials: C
authors.lastname: Ardiet
authors.forename: Lydia
authors.initials: L
authors.lastname: Campos
authors.forename: Denis
authors.initials: D
authors.lastname: Guyotat
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Vergnon
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D017209:Apoptosis; D045744:Cell Line, Tumor; D003131:Combined Modality Therapy / Q000379:methods*; D017679:Cryotherapy / Q000379:methods*; D006801:Humans; D007150:Immunohistochemistry; D020287:In Situ Nick-End Labeling; D008175:Lung Neoplasms / Q000628:therapy*; D008297:Male; D051379:Mice; D016513:Mice, SCID; D008938:Mitosis; D009336:Necrosis / Q000473:pathology; D009368:Neoplasm Transplantation; D013997:Time Factors; D014747:Vinblastine / Q000031:analogs & derivatives / Q000494:pharmacology; D000077235:Vinorelbine
chemical_list: D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D014747:Vinblastine; D000077235:Vinorelbine